SCHEMBL9816387

SCHEMBL9816387

CC(=O)Nc1c(I)c(C=O)c(I)c(NC(C)=O)c1I

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.32
ALDH1A1 P00352 2/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
KDM4E B2RXH2 2/20 0.30
HSD17B10 Q99714 2/20 0.30
GAA P10253 1/20 0.30
PKM P14618 1/20 0.30
ALOX15 P16050 1/20 0.30
HTT P42858 1/20 0.30
NAPRT Q6XQN6 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2C9 P11712 1/20 0.30
IDO1 P14902 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20471520 0.96 LMNA (0.48) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL10875389 0.84 LMNA (0.68) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL9600938 0.82 LMNA (0.42) LMNASMN1; SMN2
SCHEMBL16981764 0.80 LMNA (0.39) LMNASMN1; SMN2L3MBTL1ALDH1A1CA1
SCHEMBL16342153 0.75 LMNA (0.49) LMNASMN1; SMN2ALDH1A1KDM4ECYP1A2
SCHEMBL22680970 0.74 LMNA (0.68) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
Diatrizoic Acid SCHEMBL7615048 0.72 LMNA (0.67) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
Diatrizoic Acid SCHEMBL8508 0.72 LMNA (0.67) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL8374104 0.72 LMNA (0.55) LMNASMN1; SMN2MEN1KMT2AL3MBTL1
SCHEMBL9298885 0.72 LMNA (0.66) LMNASMN1; SMN2MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153992-B1 WATER SOLUBLE DERIVATIVES OF 3,5-DIACETO AMIDO-2,4,6-TRIIODOBENZOIC ACID AND PROCESS FOR THEIR PREPARATION AND USE Dr. Franz Köhler Chemie GmbH (DE) 1991-10-16 EP claimed
US-20180162869-A1 DRUG DELIVERY AND IMAGING CHEMICAL CONJUGATE, FORMULATIONS AND METHODS OF USE THEREOF NANOPHAGIX 2018-06-14 US disclosed
WO-2008101486-A2 COATED EXPANDABLE SYSTEM EUROCOR GMBH (DE) 2008-08-28 WO disclosed
WO-2008092435-A2 BIODEGRADABLE VASCULAR SUPPORT HEMOTEQ AG (DE) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162869-A1 DRUG DELIVERY AND IMAGING CHEMICAL CONJUGATE, FORMULATIONS AND METHODS OF USE THEREOF MTOR, RICTOR, RPTOR LMNA 4113/4885SMN1; SMN2 2369/4885MEN1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.